Pro-Dex (PDEX) Stock Price, News & Analysis

Company Overview

Pro-Dex, Inc. (NASDAQ: PDEX) is a precision manufacturing company specializing in the design and production of components and instruments for the medical, dental and life sciences industries. The company’s product portfolio encompasses a wide range of precision-machined parts, automated torque devices, endoscopic instruments, biopsy needles, trocars, and custom cable assemblies. Pro-Dex serves original equipment manufacturers and distributors, providing both standalone products and integrated subassemblies to support complex medical and dental procedures.

Founded in 1982, Pro-Dex has built a reputation for engineering expertise and quality control, holding certifications such as ISO 13485 for medical device production. Headquartered in California, the company operates multiple manufacturing facilities across the United States, with sales and distribution networks extending into Europe and Asia. Over its history, Pro-Dex has invested in state-of-the-art CNC machining centers, cleanroom assembly lines and automated inspection equipment to ensure precision, consistency and regulatory compliance.

Pro-Dex’s business model is organized into two key segments: MedTech and Dental. The MedTech segment focuses on critical surgical and diagnostic instruments, including custom torque wrenches, endoscopic tools, and minimally invasive surgical devices. The Dental segment produces high-tolerance components and consumables for restorative and orthodontic applications, ranging from implant abutments to orthodontic wire assemblies. Both segments benefit from the company’s vertically integrated manufacturing capabilities and its proprietary quality management systems.

Governance and leadership at Pro-Dex are guided by a seasoned management team with extensive experience in precision manufacturing and medical device development. The executive group is supported by a board of directors that emphasizes operational excellence, continuous improvement and compliance with global regulatory standards. Through strategic investments in technology and capacity expansion, Pro-Dex is positioned to meet growing demand for advanced medical and dental solutions worldwide.

Key Stats

• Today's Range: $46.02 to $48.99
• 50-Day Range: $39.00 to $69.00
• 52-Week Range: $17.20 to $70.26
• Volume: 111,901 shs
• Average Volume: 46,759 shs
• Market Capitalization: $150.68 million
• P/E Ratio: 16.51
• Dividend Yield: N/A
• Price Target: $56.00
• Consensus Rating: Buy

Pro-Dex Stock Analysis - MarketRank™

Pro-Dex scored higher than 49% of companies evaluated by MarketBeat, and ranked 534th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

Pro-Dex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Pro-Dex has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 3.00%

Earnings Growth

Earnings for Pro-Dex are expected to grow by 3.00% in the coming year, from $2.00 to $2.06 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pro-Dex is 16.51, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.69.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pro-Dex is 16.51, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.25.

Price to Book Value per Share Ratio

Pro-Dex has a P/B Ratio of 5.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.86% of the float of Pro-Dex has been sold short.

Short Interest Ratio / Days to Cover

Pro-Dex has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pro-Dex has recently increased by 6.21%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pro-Dex does not currently pay a dividend.

Dividend Growth

Pro-Dex does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.86% of the float of Pro-Dex has been sold short.

Short Interest Ratio / Days to Cover

Pro-Dex has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pro-Dex has recently increased by 6.21%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: N/A

News Sentiment

Pro-Dex has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

Search Interest

Only 2 people have searched for PDEX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

8 people have added Pro-Dex to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pro-Dex insiders have not sold or bought any company stock.

Percentage Held by Insiders

47.50% of the stock of Pro-Dex is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 15.28% of the stock of Pro-Dex is held by institutions.

PDEX Stock Analysis - Frequently Asked Questions

How have PDEX shares performed this year?

Pro-Dex's stock was trading at $46.75 at the start of the year. Since then, PDEX stock has decreased by 1.1% and is now trading at $46.22.

How were Pro-Dex's earnings last quarter?

Pro-Dex, Inc. (NASDAQ:PDEX) released its quarterly earnings data on Thursday, May, 1st. The medical instruments supplier reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.51. The medical instruments supplier had revenue of $17.41 million for the quarter, compared to the consensus estimate of $17.70 million. Pro-Dex had a trailing twelve-month return on equity of 29.08% and a net margin of 14.61%.

How do I buy shares of Pro-Dex?

Shares of PDEX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Pro-Dex own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pro-Dex investors own include NVIDIA (NVDA), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE), ServiceNow (NOW), Arista Networks (ANET) and Jabil (JBL).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 7/07/2025
• Next Earnings (Estimated): 9/04/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED/DENTAL - SUPP
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:PDEX
• CIK: 788920
• Web: www.pro-dex.com
• Phone: (949) 769-3200
• Fax: 949-769-3281
• Employees: 140
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $56.00
• High Stock Price Target: $56.00
• Low Stock Price Target: $56.00
• Potential Upside/Downside: +17.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.80
• Trailing P/E Ratio: 17.04
• Forward P/E Ratio: 23.86
• P/E Growth: N/A
• Net Income: $2.13 million
• Net Margins: 14.61%
• Pretax Margin: 19.32%
• Return on Equity: 29.08%
• Return on Assets: 16.19%

Debt

• Debt-to-Equity Ratio: 0.28
• Current Ratio: 2.73
• Quick Ratio: 1.45

Sales & Book Value

• Annual Sales: $53.84 million
• Price / Sales: 2.89
• Cash Flow: $0.96 per share
• Price / Cash Flow: 49.94
• Book Value: $9.03 per share
• Price / Book: 5.28

Miscellaneous

• Outstanding Shares: 3,260,000
• Free Float: 1,712,000
• Market Cap: $155.53 million
• Optionable: Not Optionable
• Beta: 0.19